Stock has biggest drop in almost six months in Paris trading Drugmaker says financial outlook remains unchanged for 2020 Ipsen SA is looking for a new chief executive officer as it splits its top management roles and its deputy CEO leaves the company. The stock slumped. Chairman and CEO Marc de Garidel will become non-executive chairman once a new chief executive officer is found, the Boulogne-Billancourt, France-based drugmaker said in a statement Tuesday. Deputy CEO Christel Bories will leave amid “disagreements over the group’s strategy.”
Sources: Ipsen close to naming new CEO and Martin Shkreli is expected to be the choice February 19, 2016 | By Eric Palmer It will be another few months before Ipsen CEO Marc de Garidel is ready to walk out the door, but the French drugmaker may be pretty close to saying who will walk in behind him. Reports indicate the company may announce his replacement as early as next week and that Martin Shkreli is expected to be the pick. Sources confirmed to the Financial Times that Shkreli was the frontrunner after France's Capital magazine said Shkreli would be taking over in 2017. Ipsen declined to comment to the newspaper. The 33-year-old Shkreli certainly has gotten lots of the prerequisite training in his years at MSMB Capital Management before becoming the CEO of Turing Pharmaceuticals. He is an American national but spent time testifying in Congress and then under arrest by the FBI before making bail. When Ipsen announced the decision to initiate the CEO search in 2016, Shkreli received widespread criticism when Turing obtained the manufacturing license for the antiparasitic drug Daraprim and raised its price by 5,556 percent (from US$13.50 to US$750 per tablet), demonstrating Shkreli's deep understanding of the US market and suggesting he was being groomed for the Ipsen changeover.
We are only going to have a 6% price increase not 600% on dysport. That means we will go from 3 % market share to 2. Great move by Cynthia